Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael C Cameron

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
The Journal of Allergy and Clinical Immunology. in Practice|September 15, 2022
Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic DermatitisKristian Reich, Peter A Lio, Robert Bissonnette, et al.
The Journal of Clinical and Aesthetic Dermatology|June 20, 2025
Tralokinumab as a Therapeutic Alternative for Dupilumab-associated Arthralgia in Atopic Dermatitis: A Multi-center Case SeriesAna B W Greenberg, Mona Shahriari, Michael C Cameron, et al.
Journal of the American Academy of Dermatology|August 20, 2021
Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trialAndrew Blauvelt, Jonathan I Silverberg, Charles W Lynde, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 8, 2015
A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapiesAlexandre Chan, Michael C Cameron, Benjamin Garden, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
The Journal of Allergy and Clinical Immunology. in Practice|September 15, 2022
Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic DermatitisKristian Reich, Peter A Lio, Robert Bissonnette, et al.
The Journal of Clinical and Aesthetic Dermatology|June 20, 2025
Tralokinumab as a Therapeutic Alternative for Dupilumab-associated Arthralgia in Atopic Dermatitis: A Multi-center Case SeriesAna B W Greenberg, Mona Shahriari, Michael C Cameron, et al.
Journal of the American Academy of Dermatology|August 20, 2021
Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trialAndrew Blauvelt, Jonathan I Silverberg, Charles W Lynde, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 8, 2015
A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapiesAlexandre Chan, Michael C Cameron, Benjamin Garden, et al.
Pageof 3